A Phase II Study of LY2157299 (Galunisertib) plus Ramucirumab in Patients with Liver Cancer

Full Title

Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma


The purpose of this study is to assess the safety and effectiveness of combining the investigational drug LY2157299 (galunisertib) with the anticancer drug ramucirumab in patients with inoperable hepatocellular carcinoma. Both drugs work by inhibiting the growth of the blood vessels that tumors needs to grow and spread. Galunisertib also activates the immune system against liver cancer.

Ramucirumab is already used to treat lung and stomach cancers; its use in this study is considered investigational. Galunisertib is taken orally (by mouth), while ramucirumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable hepatocellular carcinoma.
  • Prior sorafenib therapy is allowed, but at least 2 weeks must pass between sorafenib therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for people age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. James J. Harding at 646-888-4314.